By: Kristin Izzo, Intern Preceptor: Mary M. Julius, RD, LD, CDE and Neal Kurmas, MS, RD, LD, CDE.

Slides:



Advertisements
Similar presentations
Positive Implications of Initiating Insulin Pump Therapy at Diagnosis of Type 1 Diabetes Ramchandani, Neesha 1 ; Ten, Svetlana 1 ; Anhalt, Henry 2 ; Sinha,
Advertisements

In the name of GOD In the name of GOD.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Effect of Obesity on Kidney Transplantation Reference: Potluri K, Hou S. Obesity in kidney transplant recipients and candidates. Am J Kidney Dis. 2010;56:143–156.
PREDICTORS OF DIABETIC WOUND HEALING BY RACIAL/ETHNIC CATEGORIES Ranjita Misra 1, Lynn Lambert 2, David Vera 3, Ashley Mangaraj 3, Suchin R Khanna 3, Chandan.
The Prevalence of Male Hypotestosteronism in Type 2 Diabetics in a Southwest Virginia Population Dr. Eric Hofmeister Dr. Christopher Bishop.
Diabetes Control in Youth: The American Experience Georgeanna J. Klingensmith, MD Keystone Colorado July 2008.
Hemoglobin A 1c in Hemodialysis Patients Source: Ix JH. Hemoglobin A1c in hemodialysis patients: Should one size fit all? Clin J Am Soc Nephrol. 2010;5:1539–1541.
ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
Maenne Okunola Pharm D Candidate: University of Georgia June 3, 2012 Preceptor Dr. Ali Rahimi.
PRE-EXISTING DIABETES AND PREGNANCY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus Matthew Faiman.
Diabetes Technology Update
Diabetes: The Modern Epidemic Roy Buchinsky, MD Director of Wellness.
Closed-Loop Insulin Delivery in Children
An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.
Davida F. Kruger, MSN,APN-BC,BC-ADM Certified Nurse Practitioner Division of Endocrinology, Diabetes, Bone and Mineral Disorders Henry Ford Health System.
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
Introduction More than 2 out of 3 adults and one third of children between 6 – 19 years of age are obese or overweight (1,2). Obese individuals accrued.
* Indicates p < 0.05 indicates p < 0.05 Evaluating Clinical Pharmacist Impact on Diabetes Control* Mary Ella Hill, Pharm. D. Candidate; Orijane Dalton,
Basal Bolus: The Strategy for Managing All Diabetes Fall, 2003 Paul Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.
Toujeo® and it’s Place in Therapy
DIABETES IN THE ELDERLY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
A Diabetes Outcome Progression Trial
Symptom Distress During Breast Cancer Chemotherapy Does Race Matter? Margaret Quinn Rosenzweig, PhD, FNP-BC,AOCNP Associate Professor University of Pittsburgh.
Tresiba- insulin degludec
By: Kristin Izzo Preceptors: Elizabeth Koustis, MS, RD Pamela Jessup, MS, RD WADE PARK NUTRITION CLINIC.
Development of a Diabetes Transition Program at the Medical University of South Carolina SCTR Scientific Retreat on Transition of Care Across the Lifespan.
ADDITIONAL SLIDES FOR ASSIST WITH COMPREHENSION OF LAB CONTENT-MODULE FIVE-DM DENISE TURNER, MS-N.ED, RN, CCRN.
Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,
Journal Club Julie Shah, MD Milton S Hershey Medical Center Penn State University.
Gerti Tashko, M.D. DM Journal Club 12/16/2010. The use of exenatide with insulin is not FDA approved. The study was designed to evaluate if exenatide.
Estimating Absolute Risk Reductions Associated with Interventions in Patients with Type 2 Diabetes Jim Mold, M.D., M.P.H. Brian Firestone, MS2.
CONSUMPTION OF A DIET LOW IN ADVANCED GLYCATION END PRODUCTS FOR 4 WEEKS IMPROVES INSULIN SENSITIVITY IN OVERWEIGHT WOMEN GABBY SHERER DIABETES SELF MANAGEMENT.
Date of download: 6/24/2016 From: Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes Mellitus: A Systematic.
Bariatric Surgery for T2DM The STAMPEDE Trial. A.R. BMI 36.5 T2DM diagnosed age 24 On Metformin, glyburide  insulin Parents with T2DM, father on dialysis.
Changes in the concentration of serum C-peptide in type 2 diabetes during long-term continuous subcutaneous insulin infusion therapy Department of Internal.
Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.
Angela Aziz Donnelly April 5, 2016
Management of Morning Hyperglycemia Following Cardiac Surgery LUMC 2ICU CV-Surgical Team CV AnesthesiaNursing Staff Pharmacy StaffAnesthesia Residents.
Glycemia Treatment Strategies Used In ACCORD
High-intensity Treatment & Weight Reduction Goal Achievement with MOVE
Baseline characteristics
Use of Insulin Pump in Children with Type I Diabetes Mellitus: Effect on glycemic control and Body Mass Indices (BMI). Noura Al Hemaidi, Maryam Al Ali,
Key publication slides
Diabetes and Obesity Journal Club Carina Signori, D.O., M.P.H.
Copyright © 2006 American Medical Association. All rights reserved.
Copyright © 2004 American Medical Association. All rights reserved.
Young Children with Type 1 Diabetes Mellitus Have Low Rate of Partial Remission Sasigarn A. Bowden, Mary Duck, Robert P Hoffman Division of Endocrinology,
Effect of Insulin Resistance on Weight Loss in Overweight Children
Canagliflozin: Real World Experience
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
CV Risk of SU and Insulin
New Patient-Friendly Options for Managing Insulin Dosing
Novel Concentrated Insulins: What Benefits and for Which Patients?
Vicious Circle(s) of Hyperinsulinemia- Result in Weight Gain and Hypoglycemia Undue Or bolus Hypoglycemia Symptomatic or not!
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
Chen S, Dong Y, Kiuchi MG, et al
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.
Liraglutide Shows CV Benefit: Clinical Perspectives on the LEADER Trial
Diabetes Update: 2018 Standards of Care
Guidelines for Initiation of Therapy
Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
INSULINS Dr.R.Sajjad december INSULINS Dr.R.Sajjad december 2018.
Insulin Delivery Systems Atlanta Diabetes Associates
Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.
Twice daily regimen N=45 MDI regimen N=28 P Value
Two to 20 years: female patients, continued.
Presentation transcript:

By: Kristin Izzo, Intern Preceptor: Mary M. Julius, RD, LD, CDE and Neal Kurmas, MS, RD, LD, CDE

Citation  Granata, J., Nawarskas, A., Resch, N., Vigil, J. Evaluating the Effect of U-500 Insulin Therapy on Glycemic Control in Veterans With Type 2 Diabetes. Clinical Diabetes Journal. 2015; 33:

BACKGROUND 2,4  What is U-500 Concentrated insulin for extremely insulin resistant 1 unit U-500 = 5 unit U-100  Indications Extreme endogenous hyperinsulinemia or hyperglycemic High insulin resistance ○ Subset obese type 2 diabetes Need exogenous insulin >200 units/day (adults) Need insulin >3 units/kg (pediatrics)

OBJECTIVE 4  Determine glycemic effect for Veterans with T2DM converting from U-100 to U- 500 DESIGN  Single-Center Retrospective Chart Review

PARTICIPANTS/SETTING  VA hospital – New Mexico  25 patients Aged % Male Races represented: White (60%), black (4%), Native American (4%) and undisclosed (32%)  Those transitioning from U-100 to U-500 between April 2009 and February 2013  No intervention – retrospective chart review

MEASURES A1c % Contacts (per month) Hypoglycemia (per month) Insulin total daily dose (units/day) Injections (n/day) Weight

STATISTICAL ANALYSIS  Paired t- test Parametric data  Wilcoxon signed rank test Outliers  Spearman’s rank correlation Determined presence of correlation between variables  P>/0.05  Statistical Analysis System (SAS0

RESULTS  Patients converting from U-100 to U-500 were able to relatively improve glycemic control with significantly increasing: Incidence of hypoglycemia Daily insulin dose

CONCLUSIONS  According to this review: Converting to U-500 from U-100 insulin can be an effective alternative for diabetes management  Limitations of this study Sample size Bolus injections Weight gain

Case study Veteran RS – 59 y/o obese WM BMI = 50.6 DM2 since , A1c 8.5 Insulin pump – U500 + Aspart inj ~1 hypoglycemic event per month requiring help from another person Comorbidities Medications

Case Study Cont’d  Pump initiated 2006

PRACTICAL APPLICATION 3  Risks v. Benefits? Weight gain in obese patients Risk of hypoglycemic events 3

REFERENCES 1. American Diabetes Association. Using U-500 Insulin 2. Cochran, E., Musso, C. Gorden, P. The use of Insulin U-500 in patients with 3. Dailey AM, Gibert JA, Tannock LR. Durability of Glycemic Control using U-500 Insulin. Diabetes Research and Clinical Practice. 2012;95(3): doi: /j.diabres Granata, J., Nawarskas, A., Resch, N., Vigil, J. Evaluating the Effect of U-500 Insulin Therapy on Glycemic Control in Veterans With Type 2 Diabetes. Clinical Diabetes Journal. 2015; 33: